<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0871-3413</journal-id>
<journal-title><![CDATA[Arquivos de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Arq Med]]></abbrev-journal-title>
<issn>0871-3413</issn>
<publisher>
<publisher-name><![CDATA[ArquiMed - Edições Científicas AEFMUP ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0871-34132009000100004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Urinary Incontinence and Overactive Bladder: A Review]]></article-title>
<article-title xml:lang="pt"><![CDATA[Incontinência Urinária e Bexiga Hiperactiva]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Correia]]></surname>
<given-names><![CDATA[Soa]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Dinis]]></surname>
<given-names><![CDATA[Paulo]]></given-names>
</name>
<xref ref-type="aff" rid="A03"/>
<xref ref-type="aff" rid="A04"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lunet]]></surname>
<given-names><![CDATA[Nuno]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina Serviço de Higiene e Epidemiologia]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade do Porto Instituto de Saúde Pública ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="A03">
<institution><![CDATA[,Hospital de São João Departamento de Urologia ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
</aff>
<aff id="A04">
<institution><![CDATA[,Universidade do Porto Faculdade de Medicina Departamento de Urologia]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2009</year>
</pub-date>
<volume>23</volume>
<numero>1</numero>
<fpage>13</fpage>
<lpage>21</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S0871-34132009000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S0871-34132009000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S0871-34132009000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Overactive bladder (OAB) and urinary incontinence (UI) are common symptoms in the adult population. In 2002, the International Continence Society provided new de&#64257;nitions for lower urinary tract dysfunction but the prevalence, incidence and remission estimates of OAB and UI (and its different types) vary considerably across studies. Methodological aspects, such as the sample selection and the mode of data collection, should be taken into account when comparing results. While some risk factors are well established, others, mostly evaluated in cross-sectional studies, have not been consistently associated with the occurrence of the symptoms and some caution is necessary when attempting to de&#64257;ne causal relations. More longitudinal data are needed to con&#64257;rm &#64257;ndings from previous studies. Urinary tract dysfunctions are highly prevalent conditions among men and women and they present an important economic burden to society. Despite an important negative impact in the quality of life, urinary symptoms are often under-diagnosed and under-treated.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Os sintomas de bexiga hiperactiva (BH) e incontinência urinária (IU) são comuns na população adulta. Embora a International Continence Society tenha estabelecido novas de&#64257;nições para as disfunções do trato urinário em 2002, as estimativas de prevalência, incidência e remissão de BH e IU (e os seus diferentes tipos) variam consideravelmente na literatura existente. Para a comparação dos resultados é necessário ter em consideração aspectos metodológicos, como o método de amostragem ou a forma e instrumentos de recolha de dados. Enquanto alguns factores de risco para a incontinência urinária são já estabelecidos, para outros, maioritariamente avaliados em abordagens transversais, a literatura existente não é consensual, sendo necessário delinear e conduzir mais estudos longitudinais no sentido de con&#64257;rmar resultados existentes. Apesar da elevada prevalência entre homens e mulheres e de terem um importante impacto negativo na qualidade de vida, os sintomas de IU e BH são frequentemente sub-diagnosticados e, consequentemente, a proporção de indivíduos com tratamento é reduzida.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[urinary incontinence]]></kwd>
<kwd lng="en"><![CDATA[overactive bladder]]></kwd>
<kwd lng="en"><![CDATA[epidemiology]]></kwd>
<kwd lng="pt"><![CDATA[incontinência urinária]]></kwd>
<kwd lng="pt"><![CDATA[bexiga hiperactiva]]></kwd>
<kwd lng="pt"><![CDATA[epidemiologia]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p><B>Urinary Incontinence and Overactive Bladder</B> </p>     <p><I>A Review </I></p>     <p>&nbsp;</p>      <p>So&#64257;a Correia*&dagger;, Paulo Dinis&Dagger;&sect;, Nuno Lunet*&dagger;</P>     <p><I>*Servi&ccedil;o de Higiene e Epidemiologia, Faculdade de Medicina da Universidade    do Porto; &dagger;Instituto de Sa&uacute;de P&uacute;blica da Universidade do    Porto; </I></P >     <p><I>&Dagger;Departamento de Urologia, Hospital de S&atilde;o Jo&atilde;o, Porto;</I></P >     <p><I> &sect;Departamento de Urologia, Faculdade de Medicina da Universidade do    Porto </I></P >     <p>&nbsp;</P >     <P>Overactive bladder (OAB) and urinary incontinence (UI) are common symptoms in    the adult population. In 2002, the International Continence Society provided    new de&#64257;nitions for lower urinary tract dysfunction but the prevalence,    incidence and remission estimates of OAB and UI (and its different types) vary    considerably across studies. Methodological aspects, such as the sample    selection and the mode of data collection, should be taken into account when    comparing results. While some risk factors are well established, others, mostly    evaluated in cross-sectional studies, have not been consistently associated    with the occurrence of the symptoms and some caution is necessary when attempting    to de&#64257;ne causal relations. More longitudinal data are needed to con&#64257;rm    &#64257;ndings from previous studies. Urinary tract dysfunctions are highly    prevalent conditions among men and women and they present an important economic    burden to society. Despite an important negative impact in the quality of life,    urinary symptoms are often under-diagnosed and under-treated. </P>      <P><B>Key-words:</B> urinary incontinence; overactive bladder; epidemiology. </P>      ]]></body>
<body><![CDATA[<P>&nbsp;</P>      <P><b>Incontin&ecirc;ncia Urin&aacute;ria e Bexiga Hiperactiva </b></P>      <P>Os sintomas de bexiga hiperactiva (BH) e incontin&ecirc;ncia    urin&aacute;ria (IU) s&atilde;o comuns na popula&ccedil;&atilde;o adulta. Embora    a International Continence Society tenha estabelecido novas de&#64257;ni&ccedil;&otilde;es    para as disfun&ccedil;&otilde;es do trato urin&aacute;rio em 2002, as estimativas    de preval&ecirc;ncia, incid&ecirc;ncia e remiss&atilde;o de BH e IU (e os seus    diferentes tipos) variam consideravelmente na literatura existente. Para a compara&ccedil;&atilde;o    dos resultados &eacute; necess&aacute;rio ter em considera&ccedil;&atilde;o    aspectos metodol&oacute;gicos, como o m&eacute;todo de amostragem ou a forma    e instrumentos de recolha de dados. Enquanto alguns factores de risco para a    incontin&ecirc;ncia urin&aacute;ria s&atilde;o j&aacute; estabelecidos, para    outros, maioritariamente avaliados em abordagens transversais, a literatura    existente n&atilde;o &eacute; consensual, sendo necess&aacute;rio delinear e    conduzir mais estudos longitudinais no sentido de con&#64257;rmar resultados    existentes. Apesar da elevada preval&ecirc;ncia entre homens e mulheres e de    terem um importante impacto negativo na qualidade de vida, os sintomas de IU    e BH s&atilde;o frequentemente sub-diagnosticados e, consequentemente, a propor&ccedil;&atilde;o    de indiv&iacute;duos com tratamento &eacute; reduzida. </P>      <P><B>Palavras-chave: </B>incontin&ecirc;ncia urin&aacute;ria;    bexiga hiperactiva; epidemiologia. </P>      <P>&nbsp;</P>      <p>Urinary incontinence and overactive bladder are common conditions in the adult    population, with impact on physical, psychological and social well-being, and    represent an important burden to the economy of health services. The assessment    of the frequency of urinary incontinence and overactive bladder symptomsin speci&#64257;c    settings and the extent to which they are diagnosed and treated areimportantissues    to de&#64257;ne priorities and sustain public health strategies oriented to    the reduction of the human and economic burden of urinary dysfunctions. </P>      <p>&nbsp;</P>      <p><B>1. DEFINITION OF URINARY INCONTINENCE AND OVERACTIVE BLADDER </B></p>     <p>In 2002, the International Continence Society (ICS) provided new de&#64257;nitions    forlower urinary tract dysfunction to be compatible with the WHO ICIDH-2 (International    Classi&#64257;cation of Functioning, Disability and Health) and the ICD10 (International    Classi&#64257;cation of Diseases) (<a href="#1">1</a>). <a name="top1"></a></P >     <p>Urinaryincontinence (UI) was de&#64257;ned as&ldquo;the complaint of any involuntary    leakage of urine&rdquo;, removing from the originalde&#64257;nitionits classi&#64257;cation    as&ldquo;a socialand hygienic problem&rdquo;, which could lead to different    estimates due to its subjective aspect. The de&#64257;nition of stress urinary    incontinence was also revised to &ldquo;the complaint of involuntary leakage    on effort or exertion, or on sneezing or coughing&rdquo;. Urge urinary incontinence    is classi&#64257;ed as &ldquo;the complaint of involuntary leakage accompanied    by or immediately proceeded by urgency&rdquo; and mixed urinary incontinence    as &ldquo;the complaint of involuntary leakage associated with urgency and also    with exertion, or on sneezing or coughing&rdquo;. Overactive bladder (OAB) was    equated with the urge syndrome and the urgency-frequency syndrome and de&#64257;ned    differently than before. It is classi&#64257;ed as &ldquo;urgency, with or without    urge incontinence, usually with frequency and nocturia, in the absence of infection    or other proven aetiology&rdquo;. Increased daytime frequency of voiding is    &ldquo;the complaint by the patient who considers that he/she voids too often    by day&rdquo;; nocturia &ldquo;the complaint that the individual has to wake    at night one or more times to void&rdquo; and urgency is &ldquo;the complaint    of a sudden compelling desire to pass urine which is dif&#64257;cult to defer&rdquo;    (<a href="#1">1</a>). </P >     ]]></body>
<body><![CDATA[<p>Although individuals with urge and mixed urinary incontinence may be classi&#64257;ed    as having overactive bladder (&ldquo;wet OAB&rdquo;), a great proportion of    the subjects experiences urgency and frequency without incontinence episodes    (&ldquo;dry OAB&rdquo;) (<a href="#2">2</a>). <a name="top2"></a></P >     <p>&nbsp;</P >     <p><B>2. FREQUENCY AND RISK FACTORS </B></p>     <p>Urinary incontinence and overactive bladder are common symptoms among the adult    population worldwide, affecting approximately 200 million people (<a href="#3">3</a>)<a name="top3"></a>.    Nevertheless, and although several studies were conducted to assess the prevalence    of urinary symptoms, the estimates differ considerably across studies and settings    (<a href="#4">4-13</a>). <a name="top4"></a></P >     <p>Differences in the populations evaluated (<I>e.g.</I>: general population,    pregnant women, elderly), survey methodology (<I>e.g.</I>: telephone, mail or    personal interviews), and classi&#64257;cation of the outcome (<I>e.g.</I>:    &ldquo;any urine leakage in the previous month&rdquo;, &ldquo;any urine leakage    in the last year&rdquo;) contribute to the dif&#64257;culties in summarizing    the available evidence on this topic (<a href="#11">11</a>). <a name="top11"></a></P >     <p>Urinary incontinence has a different pathophysiology in women and men, which    is re&#64258;ected in the gender differences in the prevalence of its different    types, age distribution and risk factors. Each of these conditions is described    below, in terms of its frequency and risk factors, separately for women and    men. </P >     <p>&nbsp;</P >     <p><B>2.1. Overactive bladder</B></p>     <p>At the end of thelast century nolarge population-based studies had been conducted    to assess the frequency of overactive bladder symptoms (<a href="#14">14</a>)<a name="top14"></a>.    Epidemiologic evidence was predominantly focused on urge incontinence and did    not consider common symptoms as frequency and urgency (<a href="#4">4</a>,<a href="#8">8</a>,<a href="#14">14</a>).    <a name="top8"></a> </P >     <p>The NOBLE (National Overactive Bladder Evaluation) study, conducted in adult    population aged &ge; 18 years in the United States, reported that 16.9% of women    and 16.0% of men had overactive bladder symptoms 6. In Europe, the EPIC study    (Sweden, Italy, Canada, Germany and United Kingdom) was the &#64257;rst large    investigation assessing the lower urinary tract symptoms based on the new ICS    de&#64257;nition, in a population aged above 17 years. The prevalence of overactive    bladder was 13% in women and 11% in men (<a href="#9">9</a>)<a name="top9"></a>.    While the overall prevalence is similar in both sexes, there are gender differences    in the age-speci&#64257;c estimates and regarding the predominant symptoms.    It has been reported that women present higher prevalence before their sixties,    whereas the prevalence after this age is lower than in men<a name="top6"></a>    (<a href="#6">6</a>,<a name="top9"></a> <a href="#9">9</a>, <a href="#14">14</a>,    <a href="#15">15</a>)<a name="top15"></a>. Overactive bladder with incontinence    is the most prevalent type in women while overactive bladder without incontinence    predominates among men (<a href="#4">4</a>). </P>      ]]></body>
<body><![CDATA[<p>&nbsp;</P>      <p><B>2.2. Urinary incontinence</B></p>    <p><I>2.2.1.</I><I> WomenOverall prevalence </I></p>     <p>In the general population, estimates based on de&#64257;nitions with great    period frames for the report of urinary incontinence episodes (<I>e.g.</I>:    &ldquo;ever&rdquo;, &ldquo;in the past 12 months&rdquo;) range from 5% in women    aged 15 years or more to 69% in those over 18 years, with most studies providing    estimates between 25% and 45% (<a href="#11">11</a>). In a systematic review    published in 2003, the median prevalence of urinary incontinence among women    was 27.6% (range: 4.8-58.4%) (<a href="#7">7</a>)<a name="top7"></a>. A study    in women over 17 years in four European countries, which de&#64257;ned urinary    incontinence as any leakage or involuntary loss of urine during the preceding    30 days, presented prevalence estimates varying from 23% in Spain to 44% in    France (<a href="#10">10</a>).<a name="top10"></a> The most recent cross-national    study on urinary dysfunction (EPIC study: Canada, Germany, Italy, Sweden and    United Kingdom) reported that the proportion of incontinent adult women (&ge;    18 years) was 18%, and only in Sweden the prevalence was above 20% (<a href="#9">9</a>).  </P>      <p>Two distinct patterns have been described by different authors for the age    distribution of urinary incontinence, regardless of its type: 1) an increasing    trend with age and the highest prevalence among older women; 2) highest prevalence    in the middle aged women (around menopause), with a slight decrease up to the    seventies and rising again in older ages (<a href="#13">13</a><a name="top13"></a>,<a href="#16">16</a><a name="top16"></a>).    The review referred above shows thelatter pattern when analysing prevalence    estimates for any or occasional (ever or in the past 12 months) urinary incontinence,    whereas a steady increase up to the eighties when considering signi&#64257;cant    or regular (moderate and severe incontinence on severity index) incontinence    (<a href="#7">7</a>). </P >     <p><I>Incontinence type </I></P>      <p>Several studies do not distinguish the incontinence types and therefore the    knowledge on this topic is limited (<a href="#17">17</a>)<a name="top17"></a>.    Even so, the literature providing information regarding speci&#64257;c types    of urinary incontinence in women is consensual and refers stress incontinence    as the most prevalent, followed by mixed and urge types (<a href="#7">7</a>,<a href="#11">11</a>,<a href="#17">17-19</a>).    Minassian et al. (<a href="#7">7</a>) reported a mean prevalence of 50%, 32%    and 14%, respectively. However, this distribution is observed among young and    middle-aged women. After their forties, stress incontinence tends to decrease    and the mixed and urge types to increase (<a href="#7">7</a>,<a href="#14">14</a>,<a href="#16">16</a>).  </P>      <p>The interpretation of the &#64257;ndings referring to different types of urinary    incontinence should be cautious, considering that the ICS de&#64257;nitions    are symptom-oriented. To determine the physiopathology of the reported symptoms    (sphinctericinsuf&#64257;ciency for stress type and detrusor overactivity for    urge type) a clinicaland/or urodynamic assessment would be necessary. Sandvik    et al. (<a href="#20">20</a>)<a name="top20"></a> assessed the validity of the    questions used in surveys in comparison with gynaecologist&rsquo;s diagnosis    after urodynamic evaluation. The proportion of stressincontinenceincreased (from    51% to 77%) and the mixed type decreased (from 39% to 11%), while the proportion    of the urge type remained similar (10% <I>vs. </I>12%). Therefore, the most    frequent error when using a symptom-based questionnaire is expected to be a    misclassi&#64257;cation of stress urinary incontinence as being of the mixed    form. </P>      <p><I>Severity of urinary incontinence </I></P>      <p>Severity may be measured as the frequency of urine leakage or, more accurately,    using a severity index. The Sandvik&rsquo;s Severity index (validated using    a 48-hour pad weighing test) combinesinformation about frequency (four levels:    less than once a month; a few times a month; a few times a week; every day and/or    night) and the amount of leakage (three levels: drops; small splashes; more    than small splashes). The index value obtained by the product of the frequency    by the amount of leakage is categorized in four classes: mild, moderate, severe    and very severe (if the amount is measured using the categories &ldquo;drops&rdquo;    and &ldquo;more than drops&rdquo;, it is obtained a three level index: slight,    moderate, severe) (<a href="#21">21</a>). <a name="top21"></a></P>      ]]></body>
<body><![CDATA[<p>In Norway, the EPICONT study showed that,in women over 19 years, the prevalence    of urinary incontinence (regardless of the frequency of urine losses) was 25%    while 7% reported severe or daily episodes (<a href="#13">13</a>). </P>      <p>Severity is known to be related to increasing age and is associated with a    decrease in quality of life (<a href="#7">7</a>). Some studies refer that severe    cases seek for medical help more frequently (<a href="#7">7</a>,<a name="top12"></a><a href="#12">12</a>,<a name="top22"></a><a href="#22">22</a>,<a name="top23"></a><a href="#23">23</a>).    Minassian et al. <a name="top24"></a>(<a href="#24">24</a>) studied the variation    in prevalence of urinary incontinence and risk factors given different de&#64257;nitions,    showing that the magnitude of the association between known risk factors and    severe urinary incontinence was stronger than observed for the mild forms of    incontinence, suggesting that the latter may represent transient or non-pathologic    states that might not be clinically relevant. </P>      <p><I>Incidence and remission </I></P>      <p>Data on the incidence and remission of urinary incontinence is scarce. In 2005,    the epidemiology chapter of the International Continence Society report presented    an average annual cumulative incidence ranging from 1% to 3% in women aged less    than 60 years and from 5% up to 11% in older women (<a href="#11">11</a>). In    a review published in 2008, considering studies published after 1980, reporting    Australian data on prevalence and/or incidence in women, only two studies presented    incidence estimates <a name="top25"></a>(<a href="#25">25</a>). Liu and Andrews    (<a href="#26">26</a>)<a name="top26"></a> followed elderly participants for    2 years and the annual incidence for stress and urge type of urinary incontinence    was, respectively, 16.5% and 22.6% when considering episodes occurring &ldquo;at    least occasionally&rdquo;, and 1.6% and 2.1% when considering episodes occurring    &ldquo;often&rdquo;. </P >     <p>In the Study of Women&rsquo;s Health Across the Nation, American women aged    40-55 years were followed during 5 years and the average 1-year cumulative incidence    of at least monthly incontinent cases was 11% per year (<a href="#27">27</a>).    <a name="top27"></a> </P >     <p>In the United Kingdom, 79710 women were evaluated at home and, at the baseline,    34.2% were classi&#64257;ed as incontinent (1-year period prevalence). Among    these women, 25.2% were not incontinent in the follow-up (1year remission period).    The annual cumulative incidence was 8.8% (<a href="#28">28</a>). <a name="top28"></a></P >     <p>In Norway, 489 women aged 50-74 years were evaluated during one year. no cases    of spontaneous remission were reported and the cumulative incidence was 0.6%,    corresponding only to 3 new cases. The low estimate may be explained by the    fact that incidence estimates are vulnerable to stochastic variation when the    number of new cases is small (<a href="#29">29</a>). <a name="top29"></a></P >      <p><I>Risk factors </I></P>      <p>Severalepidemiologic studies evaluated factors associated with the occurrence    of urinary incontinence. While some determinants are well established, such    as age, obesity, parity or hysterectomy, others, mostly evaluated in cross-sectional    studies, have not been consistently associated with the occurrence of urinary    incontinence and some caution is necessary when attempting to de&#64257;ne causal    relations (<a href="#7">7</a>,<a href="#12">12</a>). </P >     <p>It is well recognized that urinary incontinence is correlated with age (<a href="#7">7</a>,<a href="#11">11</a>),    following one of the two patterns described above (<a href="#13">13</a>,<a href="#16">16</a>).    While some authors report that age is positively associated with urge and stress    urinary incontinence, others did not con&#64257;rm the latter association (<a href="#11">11</a>).  </P >     ]]></body>
<body><![CDATA[<p>Obesity has been established as a strong risk factor for stress and mixed incontinence    and a weaker association was observed with urge incontinence and overactive    bladder (<a href="#12">12</a>,<a href="#30">30</a><a name="top30"></a>,<a href="#31">31</a><a name="top31"></a>).    A recent systematic review assessing the role of overweight and obesity on urinary    incontinence reports strong evidence that, in addition to body mass index, waist-hip    ratio and thus abdominal obesity may be an independent risk factor for incontinence    in women (<a href="#32">32</a>). <a name="top32"></a></P >     <p>Pregnancy is also associated with the occurrence of urinary incontinence (<a href="#16">16</a>).    Although in many women the urinary incontinence is self-limited to pregnancy,    those developing incontinence during pregnancy have a higher predisposition    to have the symptoms later in life (<a href="#11">11</a>,<a name="top33"></a><a href="#33">33</a>,<a href="#34">34</a>)<a name="top34"></a>.    It is still questionable if pregnancy is an independent risk factor for urinary    incontinence or if the symptoms are attributable to childbirth mechanisms. Parity    is known to increase the risk of urinary incontinence, although the magnitude    of this association diminishes with age (<a href="#16">16</a>). Some studies    refer that after one delivery there is little or no additional risk, while others    suggest an increasing risk with increasing parity (<a href="#11">11</a>). Minassian    et al. (<a href="#7">7</a>) showed that most studies reported parity as a risk    factor, although they did not report on the effect of peripartum parameters,    including the mode of delivery, that could have anin&#64258;uence on the development    of urinary incontinence. Delivery is recognised as a determinant of stress urinary    incontinence in women (<a href="#11">11</a>). Rortveit et al. (<a href="#35">35</a>)<a name="top35"></a>,    in a study of 15307 Norwegian women under 65 years, reported that women with    previous caesarean section were at increased risk of stress and mixed urinary    incontinence, when compared with the nulliparous, and women with a vaginal delivery    were at greater risk compared to those who undergone caesarean. A possible protective    effect of caesarean was reviewed by Nygaard (<a href="#36">36</a>)<a name="top36"></a>    who reported that the protection conferred by this mode of delivery compared    to vaginal childbirth may be dissipated after further deliveries and decreases    with age. It is also pointed out the inconsistency in literature regarding the    risk of incontinence according to the moment of the caesarean: if before or    on labour. </P >     <p>The hormonal changes induced during peri-and post-menopausal periods may increase    the susceptibility to urinary infections and can cause storage symptoms (urinary    urgency and frequency). Some authors report that post-menopausal women are more    likely to have severe incontinence while others did not &#64257;nd differences    between premenopausal and postmenopausal groups or describe a lower prevalence    of urinary incontinence in the latter, although only for stress type and not    for urge incontinence (<a href="#7">7</a>,<a href="#11">11</a>,<a href="#37">37</a>)<a name="top37"></a>.    Oestrogen therapy is one of the treatment options for stress urinary incontinence    (<a href="#38">38</a>)<a name="top38"></a>, although a recent review did not    &#64257;nd evidence of a bene&#64257;t of oestrogen replacement therapy (<a href="#39">39</a>)<a name="top39"></a>.    One controlled multicentric study revealed that after 4 years of treatment with    a combination of oestrogen and progesterone, and independent of the age of the    women, the risk of urge and stress urinary incontinence (<a href="#40">40</a>)    <a name="top40"></a>and the severity of the incontinence actually increased    (<a href="#41">41</a>). <a name="top41" id="top41"></a></P >     <p>Also regarding hysterectomy, the &#64257;ndings areinconsistent and its role    remains controversial (<a href="#11">11</a>,<a href="#42">42</a>).<a name="top42"></a>    Although most authors tend to support that hysterectomy increases the risk of    urinary incontinence, others found no differences or a negative association    between this procedure and incontinence (<a href="#11">11</a>,<a href="#42">42-46</a>).  </P >     <p>Diabetes has been reported to increase the risk of urinary incontinence (<a href="#47">47</a>)<a name="top47"></a>    and the National Health and Nutrition Examination Survey found that two microvascular    complications caused by diabetes, macroalbuminuria and peripheral neuropathic    pain, were associated with incontinence (<a href="#48">48</a>). <a name="top48"></a></P >     <p>Functional (<I>e.g.</I>: mobility limitations, impaired vision) and cognitive    (<I>e.g.</I>: dementia or lack of mental orientation) impairment was also shown    to increase the risk of urinaryincontinence (<a href="#11">11</a>,<a href="#34">34</a>).    Constipation, smoking, family history and genitourinary prolapse have been studied    as possible risk factors for urinary incontinence in women, but the &#64257;ndings    are inconclusive (<a href="#49">49</a>). <a name="top49"></a></P >     <p><I>2.2.2.</I><I> MenPrevalence, incidence and type </I></p>     <p>The epidemiology of urinary incontinence in men has not been investigated to    the same extent as for females. Before 2002, the overall prevalence ranged from    3% to 11% (<a href="#12">12</a>). The systematic review published by Minassian    et al. (<a href="#7">7</a>), in 2003, showed that the median prevalence of urinary    incontinence among men was 10.5%, ranging from 1 to 34.1%. After the ICS new    de&#64257;nitions and recommendations in 2002, the number of population based    studies increased, and most reported lower prevalence estimates in men compared    to women (<a href="#11">11</a>). </P >     <p>The UrEpik study evaluated almost 5000 men aged 40-79 years in four countries    [Netherlands (Boxmeer); France (Auxerre); United Kingdom (Birmingham) and Korea    (Seoul)]. Self-reported urine leakage varied from 7.1% (Korea) to 14.8% (United    Kingdom) (<a href="#50">50</a>)<a name="top50"></a>. Diokno et al. (<a href="#51">51</a>)<a name="top51"></a>    described, among 21590 American men aged 18 or more years, a 12.7% prevalence    of an episode of urinary incontinence (any type) in the previous month. Urge    incontinence was the most prevalent type (45% of all cases) except among participants    with 18-35 years who reported a higher proportion of stress incontinence. In    the EPIC study, the overall prevalence was 5.4% and, as in the previous American    study, urge incontinence was the predominant type (overall prevalence: 1.2%;    stress and mixed type: 0.6% each) (<a href="#9">9</a>). </P >     <p>Up to now the literature is consensual describing a steady increase of the    urge type incontinence with increasing age, which is the major contributor to    the overall increase in the frequency of urinary incontinence with age in men.    Mixed urinary incontinence also tends to increase with age, while stress incontinence    decreases after the forties (<a href="#9">9</a>,<a href="#11">11</a>,<a href="#51">51</a>).  </P >     ]]></body>
<body><![CDATA[<p>Incidence data among men is even scarcer than for women. McGrother et al. (<a href="#28">28</a>)    presented 39.6% as the 1-year remission proportion (baseline prevalence 14.2%)    and, for the same time period, a cumulative incidence of 3.8%. In Australia,    men aged 65 or more years were followed during 2 years. The incidence considering    episodes occurring &ldquo;at least occasionally&rdquo; was 11.9% for stress    incontinence and 17.4% for urge incontinence. For the &ldquo;often&rdquo; episodes    it was, respectively, 2.2% and 3.4% (<a href="#26">26</a>). </P >     <p><I>Risk factors </I></P >     <p>Usually urinary incontinence in men is not an isolated problem and exists with    other co-morbidities, such as urogenital symptoms or erectile dysfunction (<a href="#11">11</a>).    Increasing age is associated with a higher proportion of incontinent cases (<a name="top5"></a><a href="#5">5</a>,<a href="#12">12</a>,<a href="#52">52</a>)<a name="top52"></a>    and other urinary symptoms, namely those related to overactive bladder (<I>e.g.</I>:    urgency, nocturia) or urinary tract infections showed to be strongly associated    with urinary incontinence in men (<a href="#5">5</a>,<a href="#12">12</a>).  </P >     <p>Prostatectomy, especially radical prostatectomy, is well established as a risk    factor for urinary incontinence in men and the risk seems to increase with the    increasing age at time of surgery (<a href="#11">11</a>,<a href="#34">34</a>)<a name="top34"></a>.    As for women, partial or total immobilization is described to be related with    an increase of urinary incontinence, especially among the elderly. Also men    having neurological disorders, such as Parkinson, and those who suffered a stroke    are more likely to develop incontinence (<a href="#11">11</a>). <a name="top11"></a></P >     <p>&nbsp;</P >     <p><B>3. MANAGEMENT OF URINARY SYMPTOMS </B></p>     <p><b>3.1. Awareness and help-seeking behaviour</b> </p>     <p>Urinary incontinence and overactive bladder have an important negative impact    in the quality of life (QoL), regarding physical, social, psychological, sexual    well-being and daily activities (<a href="#53">53</a>)<a name="top53"></a>.    Even so, urinary symptoms are often under-diagnosed and under-treated (<a href="#10">10</a>,<a href="#50">50</a>,<a href="#54">54</a><a name="top54"></a>,<a href="#55">55</a>.)<a name="top55"></a>  </P >     <p>Studies on care seeking behaviours are consensualon the reasons for not getting    professionalcare. Generally, the fact that urinary incontinence is disregarded    as a serious problem and seen as part of the normal ageing process, the low    expectations of a possible effective treatment, and the embarrassment or fear    of exposing this situation to health professionals may lead to low consultation    rates and a low proportion of diagnosed patients (<a href="#7">7</a>,<a href="#12">12</a>,<a href="#23">23</a>,<a href="#56">56</a>)<a name="top56"></a>.    The report of the symptoms to health professionals is associated with its increasing    severity and/or its impact on quality of life (<a href="#12">12</a>,<a href="#22">22</a>,<a href="#23">23</a>,<a href="#28">28</a>,<a href="#50">50</a>,<a href="#57">57</a>).    <a name="top57"></a> </P >     <p>McGrother et al. (<a href="#28">28</a>) reported a similar proportion of men    and women having a medical consultation due to abnormal urinary storage symptoms    (12% and 13%, respectively). Independently of quality of life, men (aware of    the context of prostate cancer) and older participants were more likely to seek    for help (<a href="#28">28</a>). In the UrEpik study, among men with urine leakage,    25.6% of the European participants and only 9.0% of the men in Seoul consulted    a doctor (<a href="#50">50</a>). Hunskaar et al. (<a href="#10">10</a>) reported    that in incontinent women, the proportion of those having medical consultations    varied form 16% in Spain to 36% among the German patients. </P >     ]]></body>
<body><![CDATA[<p><B>3.2. Treatment and costs </B></p>     <p>The costs of urinary incontinence and overactive bladder are related to diagnosis,    treatment, use of pads, routine care, co-morbidities or loss of productivity    (<a href="#58">58</a>),<a name="top58"></a> but most of the economic burden    is underestimated considering the low proportion of incontinent subjects having    medical consultations for that reason (<a href="#59">59</a>). <a name="top59"></a></P >     <p>In 2000, the total cost of overactive bladder to health care systems (drug    use, medical visits, co-morbidities, pads use)in &#64257;ve countries (Germany,    Italy, Spain, Sweden and United Kingdom) was estimated to be 4.2 billion Euros    and it was expected to increase to 5.2 billion in 2020 (<a href="#59">59</a>).    PURE (Prospective urinary incontinence research), a non-interventional study    of women seeking treatment for urinary incontinence in an outpatient setting,    showed a mean total urinary incontinence annual costs ranging from 359&euro;    in the UK/Ireland patients to 655&euro; in Spain, and personal costs vary according    the country health care system, namely on reimbursement policies (<a href="#60">60</a>).    <a name="top60"></a> </P >     <p>The management and costs of urinary symptoms vary among incontinent patients.    Half of European women reporting urine leakage referred the use of pads, 5%    were taking drugs and 5% had surgery for urinary incontinence problems (<a href="#10">10</a>)<a name="top10"></a>.    In the United States, from 13% of men with urine leakage episodes, 47% consulted    a physician and 30% of those were taking prescription medicines, 18% underwent    some kind of surgery and 4% were using a catheter (<a href="#51">51</a>). <a name="top51"></a></P >     <p>So, it is not surprising that most economic expenditure may be attributable    to the use of pads, surgicalprocedures, and pharmacologicaltreatments. Conservative    treatments (<I>e.g.</I>: pelvic &#64258;oor exercises, bladder training, etc.)    are usually attributed a lower economic burden (<a href="#60">60</a>). </P >     <p>Treatment options for patients suffering of urinary incontinence differ according    the physiopathology of incontinence. While urge incontinence responds to pelvic    &#64258;oor muscle treatment and anticholinergic medication, for stress incontinence    the pharmacologic approach may not have the same impact (<a href="#54">54</a>).    It is suggested that pelvic muscle training should be included in &#64257;rst-line    conservative management programs for both urge and stress incontinence. Individuals    with urge incontinence or overactive bladder should also adopt other behavioural    changes, such as &#64258;uid management or scheduled voiding intervals (<a href="#49">49</a>,<a href="#61">61</a>)<a name="top61"></a>.    The guidelines on urinary incontinence from the European Association of Urology    recommend lifestyle interventions and pelvic &#64258;oor muscle training or    bladder retraining as the initial management of urinary incontinence for men    and women (<a href="#62">62</a>). <a name="top62"></a></P >     <p>The pharmacological approach is common in overactive bladder / urge incontinence    and the ef&#64257;cacy of anticholinergic drugs, which suppress bladder contractions,    is well established (<a href="#63">63</a>)<a name="top63"></a>. The most frequently    used drugs are oxybutynin, trospium and propiverine (<a href="#63">63-66</a>)    although some authors refer their adverse effects (<I>e.g.</I>: dry mouth, constipation)    as possible reasons for discontinuation (<a href="#49">49</a>). Of late more    recently developed molecules such as solifenacin and darifenacin, which speci&#64257;cally    block the M3 muscarinic receptors, are also available. These new drugs might    have some advantage in achieving clinical results with fewer side effects. However    patients&rsquo; response to treatment varies individually and some can respond    well to one anti muscarinic and not to another despite molecular composition    (<a href="#67">67</a>).<a name="top67"></a> Cystoscopic injection of botulinum    toxin in the detrusor muscle has been studied and is a promising alternative    for urge incontinence refractory to other pharmachological treatments <a name="top68"></a>(<a href="#68">68</a>,<a href="#69">69</a>).    <a name="top69"></a></P >     <p>The absence of effective and well tolerated pharmacological treatments for    stress urinary incontinence limits the choices (<a href="#70">70</a>)<a name="top70"></a>.    The pharmacotherapy approach before surgical procedures includes alfa-adrenergic    drugs, tricyclic antidepressants such as imipramine, and oestrogen (<a href="#70">70</a>),    although the evidence for the latter is not consensual (<a href="#40">40</a>,<a href="#41">41</a>).    Duloxetine, a serotonin and noradrenaline reuptake inhibitor, is in phase III    controlled trials and it is suggested that can signi&#64257;cantly improve the    quality of life of women with stress urinary incontinence (<a href="#71">71</a>).    <a name="top71"></a> </P >     <p>Surgery is used especially for stress urinary incontinence and it is rarely    indicated for urge incontinence (<a href="#49">49</a>). Even so, it seems that    electrical stimulation and sacral neuromodulation improve urge urinary incontinence    and are recommended (<a href="#34">34</a>,<a href="#62">62</a>). The most frequent    surgical procedures for stress incontinence are sling procedures and colposuspension    in women or arti&#64257;cial sphincter in men (<a href="#49">49</a>,<a href="#62">62</a>).  </P >     <p>Meanwhile, surgeries for stress incontinence, as vaginal tapes or sling procedures    have been associated with a growing number of individuals with suboptimal results    and there are few studies providing non-surgical treatment options for women    with failed surgeries (<a href="#72">72</a>)<a name="top72"></a>. However &ldquo;re-do&rdquo;    surgery seems to meet with some measure of success (<a href="#73">73</a>). <a name="top73"></a></P >     ]]></body>
<body><![CDATA[<p>&nbsp;</P >     <p><B>4. METHODOLOGICAL ISSUES</B> </p>     <p>The wide regional variation in the frequency of urinary symptoms re&#64258;ects    the methodological heterogeneity across studies, as well as cultural differences.    In addition to subject-speci&#64257;c issues, such as the selected sex and age    groups, the methods used to select and evaluate the participants are important    issues in population-based surveys (<a href="#74">74</a>). <a name="top74" id="top74"></a></P >     <p>The assessment of urinary dysfunctions using questionnaires instead of clinical    or urogynaecologic evaluations may contribute to an overestimatimation of mixed    urinaryincontinence and underestimation of the frequency of the stress type,    as referred by Sandvik et al. (<a href="#20">20</a>). Kirschner-hermanns et    al. (<a href="#75">75</a>) <a name="top75"></a>showed a poor correlation between    the assessment of urinary incontinence using questionnaires and video urodynamic    testing in adults aged 65 or more years. Although urodynamics may be more precise,    it is an invasive method of evaluating urinary dysfunction and in a clinical    basis, individuals who respond satisfactorily to conservative care have no need    for urodynamic studies (<a href="#76">76</a>)<a name="top76"></a>. Additionally,    in epidemiological research, it would be too expensive to carry out studies    of thousands of participants across wide geographical areas not using questionnaires    as the assessment tool for urinary symptoms. Therefore, the International Consultation    on Incontinence Questionnaire (ICIQ) develops valid instruments universally    applicable both in clinical practice and research (<a href="#77">77</a>).<a name="top77"></a>    The European Association of Urology recommends the ICIQ-SF, a questionnaire    on symptom scores and quality of life (<a href="#62">62</a>). </P >     <p>The methods of questionnaire administration may also in&#64258;uence data quality, namely regarding sensitive questions as may be urinary topics. </P >     <p>When analysing the accuracy of survey reports about sensitive questions (e.g.    illicit drug use, sexual behaviour or abortion), Tourangeau and Yan (<a href="#78">78</a>)<a name="top78"></a>    showed that most studies comparing modes of data collection on these topics    presented higher prevalence estimates on self-administered questionnaires than    when questions were administered by an interviewer. Rhodes et al. (<a href="#79">79</a>)    <a name="top79" id="top79"></a>compared the effect of modes of administration    (selfadministered questionnaires, oral face-to-face in-clinic interview, and    telephone interview) on responses to the American Urological Association Symptom    Index among men. The report of urinary symptoms was generally higher in self-completed    questionnaires when compared with clinical evaluations (face-to-face) and also    higher than in telephone interviews, partly because of the possible embarrassment    when reporting to an interviewer. Nevertheless self-administered questionnaires    may result in suboptimalcompleteness and accuracy of data (e.g. comprehension    dif&#64257;culties among less educated participants, more neutral responses,    as the &ldquo;I don&rsquo;t know&rdquo; options) which may reduce its validity    (<a href="#80">80</a>). <a name="top80"></a></P >     <p>Telephone surveys are an attractive option to collect health related data and    may be a good cost-effective strategy, providing accurate estimates on urinary    symptoms (or, at least, underestimate the true prevalence, as referred above)    as regarding several other health issues (<a href="#6">6</a>,<a href="#9">9</a>,<a href="#14">14</a>,<a href="#81">81</a><a name="top81"></a>,<a href="#82">82</a>).    <a name="top82"></a> </P >     <p>Allowing the coverage of large populations over wide geographical areas with    a reasonable ef&#64257;ciency, these surveys are widely used and the selection    of participantsis frequently done using random-digit dialling orlist-assisted    frames schemes <a name="top83"></a>(<a href="#83">83</a>). The sampling strategy    is also an issue of mainimportancein the survey design considering the increasing    trends in non-coverage and non-response rates and what may be the effect of    these problems on the validity of the estimates produced (<a href="#84">84</a>).    <a name="top84"></a> </P >     <p>&nbsp;</P >     <p><B>CONCLUSIONS</B> </p>    ]]></body>
<body><![CDATA[<p>Urinary tract dysfunctions are highly prevalent conditions among men and women and with a wide geographic distribution. They present an important economic burden to society. Severalrisk factors are described, especially for women, but more longitudinal data are needed to con&#64257;rm &#64257;ndings from previous studies and also to provide more information on incidence and remission rates. </P >    <p>Despite its impact on quality of life and the available treatment options, a minority of patients seeks for help and so, a low proportion is treated. </P >     <p>Estimates on prevalence and incidence of these diseases vary considerably across    studies. Therefore, methodological aspects, such as the sample selection and    the mode of data collection, should be taken into account when comparing results.  </P >     <p>&nbsp;</P >     <p><B>REFERENCES </B></p>     <p><a href="#top1">1</a> <a name="1"></a>-Abrams P, Cardozo L, Fall M, et al.    The standardisation of terminology of lower urinary tract function: report from    the Standardisation Sub-committee of the International Continence Society. Neurourol    Urodyn 2002;21:167-78. </P >     <p><a href="#top2">2</a> <a name="2"></a>-Tubaro A. De&#64257;ning overactive    bladder: epidemiology and burden of disease. Urology 2004;64(6 Suppl 1):2-6.  </P >     <p><a href="#top3">3</a> <a name="3"></a>-WHO. World Health Organization Calls    First International Consultation on Incontinence. Press Release WHO/49. 1998.    Available from: <a href="http://www.who.int/inf-pr-1998/en/pr98-49.html" target="_blank">http://www.who.int/inf-pr-1998/en/pr98-49.html</a>  </P >     <p><a href="#top4">4</a> <a name="4"></a>-TubaroA, PalleschiG. Overactive bladder:    epidemiology and social impact. Curr Opin Obstet Gynecol 2005;17:507-11. </P >     <p><a href="#top5">5</a><a name="5"></a> -Thom D. Variationin estimates of urinaryincontinence    prevalence in the community: effects of differences in de&#64257;nition, population    characteristics, and study type. J Am Geriatr Soc 1998;46:473-80. </P >     ]]></body>
<body><![CDATA[<p><a href="#top6">6</a> <a name="6"></a>-Stewart WF, Van Rooyen JB, Cundiff GW,    et al. Prevalence and burden of overactive bladder in the United States. World    J Urol 2003;20:327-36. </P >     <p><a href="#top7">7</a> <a name="7"></a>-Minassian VA, Drutz HP, Al-Badr A. Urinary    incontinence as a worldwide problem. Int J Gynaecol Obstet 2003;82:327-38. </P >     <p><a href="#top8">8</a><a name="8"></a> -Milsom I, Stewart W, Thuroff J. The    prevalence of overactive bladder. Am J Manag Care.2000;6(11 Suppl):S565-73.  </P >     <p><a href="#top9">9</a> <a name="9"></a>-Irwin DE, Milsom I, Hunskaar S, et al.    Population-based survey of urinaryincontinence, overactive bladder, and other    lower urinary tract symptoms in &#64257;ve countries: results of the EPIC study.    Eur Urol 2006;50:1306-14; discussion 14-5. </P >     <p><a href="#top10">10</a> <a name="10"></a>-Hunskaar S, Lose G, Sykes D, Voss    S. The prevalence of urinary incontinence in women in four European countries.    BJU Int 2004;93:324-30. </P >     <p><a href="#top11">11</a> <a name="11"></a>-Hunskaar S, Burgio K, Clark A, et    al. Incontinence - Basics and Evaluation. <I>3rd International Consultation    on Incontinence</I>: International Continence Society 2005. </P >     <p><a href="#top12">12</a> <a name="12"></a>-Hunskaar S, Arnold EP, Burgio K,    Diokno AC, Herzog AR, Mallett VT. Epidemiology and natural history of urinary    incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:301-19. </P >     <p><a href="#top13">13</a><a name="13"></a> -Hannestad YS, Rortveit G, Sandvik    H, Hunskaar S. A community-based epidemiologicalsurvey of female urinary incontinence:    the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of    Nord-Trondelag. J Clin Epidemiol 2000;53:1150-7. </P >     <p><a href="#top14">14</a> <a name="14"></a>-Milsom I,Abrams P, Cardozo L, Roberts    RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder    and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.  </P >     <p><a href="#top15">15</a><a name="15"></a> -Homma Y, Yamaguchi O, Hayashi K.    An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 2005;96:1314-8.  </P >     ]]></body>
<body><![CDATA[<p><a href="#top16">16</a><a name="16"></a> -Hunskaar S, Burgio K, Diokno A, Herzog    AR, Hjalmas K, Lapitan MC. Epidemiology and natural history of urinary incontinence    in women. Urology 2003;62(4 Suppl 1):16-23. </P >     <p><a href="#top17">17</a><a name="17"></a> -HampelC,ArtibaniW, Espuna Pons M,    et al. Understanding the burden of stress urinaryincontinencein Europe: a qualitative    review of the literature. Eur Urol 2004;46:15-27. </P >     <p><a href="#top17">18</a><a name="18"></a> -Hampel C, Wienhold D, Benken N, Eggersmann    C, Thuroff JW. De&#64257;nition of overactive bladder and epidemiology of urinary    incontinence. Urology 1997;50(6A Suppl):4-14; discussion 5-7. </P >     <p><a href="#top17">19</a><a name="19"></a> -Diokno AC, Estanol MV, Mallett V.    Epidemiology of lower urinary tract dysfunction. Clin Obstet Gynecol 2004;47:36-43.  </P >     <p><a href="#top20">20</a><a name="20"></a> -Sandvik H, Hunskaar S, VanvikA, Bratt    H, SeimA, Hermstad R. Diagnostic classi&#64257;cation of female urinary incontinence:    an epidemiological survey corrected for validity. J Clin Epidemiol 1995;48:339-43.  </P >     <p><a href="#top21">21</a><a name="21"></a> -Sandvik H, Seim A, Vanvik A, Hunskaar    S. A severity index for epidemiological surveys of female urinary incontinence:    comparison with 48-hour pad-weighing tests. Neurourol Urodyn 2000;19:137-45.  </P >     <p><a href="#top22">22</a><a name="22"></a> -O&rsquo;Donnell M, Lose G, Sykes    D, Voss S, Hunskaar S. Help-seeking behaviour and associated factors among women    with urinary incontinence in France, Germany, Spain and the United Kingdom.    Eur Urol 2005;47:385-92; discussion 92. </P >     <p><a href="#top23">23</a><a name="23"></a> -Gasquet I, Tcherny-Lessenot S, Gaudebout    P, Bosio Le Goux B, Klein P, Haab F. In&#64258;uence of the severity of stress    urinary incontinence on quality of life, health care seeking, and treatment:    A national cross-sectional survey. Eur Urol 2006;50:818-25. </P >     <p><a href="#top24">24</a> <a name="24"></a>-Minassian VA, Stewart WF, Wood GC.    Urinaryincontinence in women: variation in prevalence estimates and risk factors.    Obstet Gynecol 2008;111(2 Pt 1):324-31. </P >     <p><a href="#top25">25</a><a name="25"></a> -Botlero R, Urquhart DM, Davis SR,    Bell RJ. Prevalence and incidence of urinary incontinence in women: review of    the literature and investigation of methodological issues. Int J Urol 2008;15:230-4.  </P >     ]]></body>
<body><![CDATA[<p><a href="#top26">26</a> <a name="26"></a>-Liu C, Andrews GR. Prevalence and    incidence of urinary incontinence in the elderly: a longitudinal study in South    Australia. Chin Med J (Engl) 2002;115:119-22. </P >     <p><a href="#top27">27</a><a name="27"></a> -Waetjen LE, Liao S, Johnson WO, et    al. Factors associated with prevalent and incident urinary incontinence in a    cohort of midlife women: a longitudinal analysis of data: study of women&rsquo;s    health across the nation. Am J Epidemiol 2007;165:309-18. </P >     <p><a href="#top28">28</a> <a name="28"></a>-McGrother CW, Donaldson MM, Shaw    C, et al. Storage symptoms of the bladder: prevalence, incidence and need for    services in the UK. BJU Int 2004;93:763-9. </P >     <p><a href="#top29">29</a> <a name="29"></a>-HoltedahlK, Hunskaar S. Prevalence,    1-yearincidence and factors associated with urinary incontinence: a population    based study of women 50-74 years of age in primary care. Maturitas 1998;28:205-11.  </P >     <p><a href="#top30">30</a><a name="30"></a> -Lawrence JM, Lukacz ES, Liu IL, Nager    CW, Luber KM. Pelvic &#64258;oor disorders, diabetes, and obesityin women: &#64257;ndings    from the Kaiser Permanente Continence Associated Risk Epidemiology Study. Diabetes    Care 2007;30:2536-41. </P >     <p><a href="#top31">31</a> <a name="31"></a>-Dallosso HM, McGrother CW, Matthews    RJ, Donaldson MM. The association of diet and other lifestyle factors with overactive    bladder and stress incontinence: a longitudinal study in women. BJU Int 2003;92:69-77.  </P >     <p><a href="#top32">32</a><a name="32"></a> -Hunskaar S. A systematic review of    overweight and obesity as risk factors and targets for clinical intervention    for urinary incontinence in women. Neurourol Urodyn 2008;27:749-57. </P >     <p><a href="#top33">33</a><a name="33"></a> -Viktrup L, Rortveit G, Lose G. Risk    of stress urinary incontinence twelve years after the &#64257;rst pregnancy    and delivery. Obstet Gynecol 2006;108:248-54. </P >     <p><a href="#top34">34</a> <a name="34"></a>-Shamliyan T, Wyman J, Bliss DZ, Kane    RL, Wilt TJ. Prevention of urinary and fecal incontinence in adults. Evid Rep    Technol Assess (Full Rep) 2007:1-379. </P >     <p><a href="#top35">35</a><a name="35"></a> -Rortveit G, DaltveitAK, Hannestad    YS, Hunskaar S. Urinary incontinence after vaginal delivery or cesarean section.    N Engl J Med 2003;348:900-7. </P >     ]]></body>
<body><![CDATA[<p><a href="#top36">36</a><a name="36"></a> -Nygaard I. Urinary incontinence:    is cesarean delivery protective? Semin Perinatol 2006;30:267-71. </P >     <p><a href="#top37">37</a><a name="37"></a> -Tinelli A, Tinelli R, Perrone A,    Malvasi A, Cicinelli E, Cavaliere V, et al. [Urinary incontinence in postmenopausal    period: clinical and pharmacological treatments]. Minerva Ginecol. 2005 Dec;57(6):593-609.  </P >     <P   align="" ><a href="#top38">38</a> <a name="38"></a>-Castro-Diaz D, Amoros MA. Pharmacotherapy    for stress urinary incontinence. Curr Opin Urol 2005;15:227-30. </P >     <P   align="" ><a href="#top39">39</a> <a name="39"></a>-Jung BH, Jeon MJ, Bai SW. Hormone-dependent    aging problems in women. Yonsei Med J 2008;49:345-51. </P >     <p><a href="#top40">40</a> <a name="40"></a>-Steinauer JE, Waetjen LE, Vittinghoff    E, Subak LL, Hulley SB, Grady D, et al. Postmenopausal hormone therapy: does    it cause incontinence? Obstet Gynecol 2005;106(5 Pt 1):940-5. </P >     <p><a href="#top41">41</a> <a name="41"></a>-Grady D, Brown JS, Vittinghoff E,    Applegate W, Varner E, Snyder T. Postmenopausalhormones andincontinence: the    Heart and Estrogen/Progestin Replacement Study. Obstet Gynecol 2001;97:116-20.  </P >     <p><a href="#top42">42</a><a name="42"></a> -Magos A. Does hysterectomy cause    urinary incontinence? Lancet 2007;370:1462-3. </P >     <p><a href="#top42">43</a> <a name="43"></a>-Thakar R, Ayers S, Clarkson P, Stanton    S, Manyonda I. Outcomes after total versus subtotal abdominal hysterectomy.    N Engl J Med 2002;347:1318-25. </P >     <p><a href="#top42">44</a> <a name="44"></a>-Engh MA, Otterlind L, Stjerndahl    JH, Lofgren M. Hysterectomy and incontinence: a study from the Swedish national    register for gynecological surgery. Acta Obstet Gynecol Scand 2006;85:614-8.  </P >     <p><a href="#top42">45</a><a name="45"></a> -de Tayrac R, Chevalier N, Chauveaud-LamblingA,    Gervaise A, Fernandez H. Is vaginal hysterectomy a risk factor for urinary incontinence    at long-term follow-up? Eur J Obstet Gynecol Reprod Biol 2007;130:258-61. </P >     ]]></body>
<body><![CDATA[<p><a href="#top42">46</a><a name="46"></a> -Altman D, Zetterstrom J, Schultz    I, et al. Pelvic organ prolapse and urinary incontinence in women with surgically    managed rectal prolapse: a population-based case-control study. Dis Colon Rectum    2006;49:28-35. </P >     <p><a href="#top47">47</a> <a name="47"></a>-Hill SR, Fayyad AM, Jones GR. Diabetes    mellitus and female lower urinary tract symptoms: a review. Neurourol Urodyn    2008;27:362-7. </P >     <p><a href="#top48">48</a><a name="48"></a> -Brown JS, Vittinghoff E, Lin F, Nyberg    LM, Kusek JW, Kanaya AM. Prevalence and risk factors for urinary incontinence    in women with type 2 diabetes and impaired fasting glucose: &#64257;ndings from    the National Health and Nutrition Examination Survey (NHANES) 2001-2002. Diabetes    Care 2006;29:1307-12. </P >     <p><a href="#top49">49</a><a name="49"></a> -Norton P, Brubaker L. Urinary incontinence    in women. Lancet 2006;367:57-67. </P >     <p><a href="#top50">50</a> <a name="50"></a>-Boyle P, Robertson C, Mazzetta C,    Keech M, Hobbs FD, Fourcade R, et al. The prevalence of male urinary incontinence    in four centres: the UREPIK study. BJU Int. 2003 Dec;92(9):943-7. </P >     <p><a href="#top51">51</a> <a name="51"></a>-Diokno AC, Estanol MV, Ibrahim IA,    Balasubramaniam M. Prevalence of urinary incontinence in community dwelling    men: a cross sectional nationwide epidemiological survey. Int Urol Nephrol 2007;39:129-36.  </P >     <p><a href="#top52">52</a><a name="52"></a> -Dubeau CE. The aginglower urinary    tract. J Urol2006;175(3 Pt 2):S11-5. </P >     <p><a href="#top53">53</a> <a name="53"></a>-Donovan J, Bosch R, Gotoh M, et al.    Incontinence: Basics and Evaluation - Symptom and quality of life Asessement.    <I>3rd InternationalConsultation on Incontinence</I>: International Continence    Society 2005. </P >     <p><a href="#top54">54</a><a name="54"></a> -Santiagu SK, Arianayagam M, Wang    A, Rashid P. Urinary incontinence-pathophysiology and management outline. Aust    Fam Physicia 2008;37:106-10. </P >     <p><a href="#top55">55</a> <a name="55"></a>-Diokno AC, Sand PK, Macdiarmid S,    Shah R, Armstrong RB. Perceptions and behaviours of women with bladder control    problems. Fam Pract. 2006 Oct;23(5):568-77. </P >     ]]></body>
<body><![CDATA[<!-- ref --><p><a href="#top56">56</a> <a name="56"></a>-Moura B. [Incontin&ecirc;ncia urin&aacute;ria    feminina.]. Rev Port Clin Geral 2005;21:11-20. </P >     &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000153&pid=S0871-3413200900010000400001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><a href="#top57">57</a><a name="57"></a> -HuangAJ, Brown JS, KanayaAM, et al.    Quality-of-lifeimpact and treatment of urinary incontinence in ethnically diverse    older women. Arch Intern Med 2006;166:2000-6. </P >     <p><a href="#top58">58</a> <a name="58"></a>-Wagner TH, HuTW. Economic costs of    urinaryincontinence. Int Urogynecol J Pelvic Floor Dysfunct 1998;9:127-8. </P >     <p><a href="#top59">59</a> <a name="59"></a>-Reeves P, Irwin D, Kelleher C, et    al. The current and future burden and cost of overactive bladder in &#64257;ve    European countries. Eur Urol 2006;50:1050-7. </P >     <p><a href="#top60">60</a> <a name="60"></a>-Papanicolaou S, Pons ME, Hampel C,    et al. Medical resource utilisation and cost of care for women seeking treatment    for urinary incontinence in an outpatient setting. Examples from three countries    participating in the PURE study. Maturitas 2005;52 (Suppl 2):S35-47. </P >     <p><a href="#top61">61</a><a name="61"></a> -Milne JL. Behavioral therapies for    overactive bladder: making sense of the evidence. J Wound Ostomy Continence    Nurs 2008;35:93-101; quiz 2-3. </P >     <p><a href="#top62">62</a><a name="62"></a> -Guidelines on Urinary Incontinence    2006 October 2008 [cited October 2008];Available from: <a href="http://www.uroweb.org/%01%FBledmin/tx_eauguidelines/16%20Urinary%20Incontinence.pdf" target="_blank">http://www.uroweb.org/&#64257;ledmin/tx_eauguidelines/16%20Urinary%20Incontinence.pdf</a>  </P >     <p><a href="#top63">63</a> <a name="63"></a>-Alhasso AA, McKinlay J, Patrick K,    Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive    bladder syndrome in adults. Cochrane Database Syst Rev 2006:CD003193. </P >     <p><a href="#top63">64</a><a name="64"></a> -Roxburgh C, Cook J, Dublin N.Anticholinergic    drugs versus other medications for overactive bladder syndromein adults. Cochrane    Database Syst Rev 2007:CD003190. </P >     <p><a href="#top63">65</a> <a name="65"></a>-Abramov Y, Sand PK. Oxybutynin for    treatment of urge urinary incontinence and overactive bladder: an updated review.    Expert Opin Pharmacother 2004;5:2351-9. </P >     ]]></body>
<body><![CDATA[<p><a href="#top63">66</a> <a name="66"></a>-Salvatore S, Serati M, Bolis P. Tolterodine    for the treatment of overactive bladder. Expert Opin Pharmacother 2008;9:1249-55.  </P >     <p><a href="#top67">67</a><a name="67"></a> -Andersson KE, Yoshida M. Antimuscarinics    and the overactive detrusor-which is the main mechanism of action? Eur Urol    2003;43:1-5. </P >     <p><a href="#top68">68</a><a name="68"></a> -Giannantoni A, Mearini E, Del Zingaro    M, Santaniello F, Porena M. Botulinum A toxin in the treatment of neurogenic    detrusor overactivity: a consolidated &#64257;eld of application. BJU Int 2008;102    (Suppl 1):2-6. </P >     <p><a href="#top69">69</a> <a name="69"></a>-Duthie J, Wilson DI, Herbison GP,    Wilson D. Botulinum toxininjections for adults with overactive bladder syndrome.    Cochrane Database Syst Rev 2007:CD005493. </P >     <p><a href="#top70">70</a> <a name="70"></a>-Zinner NR, Koke SC, Viktrup L. Pharmacotherapy    for stress urinary incontinence : present and future options. Drugs 2004;64:1503-16.  </P >     <p><a href="#top71">71</a> <a name="71"></a>-Mariappan P, Alhasso A, Ballantyne    Z, Grant A, N&rsquo;Dow J. Duloxetine, a serotonin and noradrenaline reuptakeinhibitor    (SNRI) for the treatment of stress urinary incontinence: a systematic review.    Eur Urol 2007;51:67-74. </P >     <p><a href="#top72">72</a><a name="72"></a> -Appell RA, Davila GW. Treatment options    for patients with suboptimal response to surgery for stress urinary incontinence.    Curr Med Res Opin 2007;23:285-92. </P >     <p><a href="#top73">73</a><a name="73"></a> -Moore RD, Gamble K, Miklos JR. Tension-free    vaginal tape sling for recurrent stress incontinence after transobturator tape    sling failure. Int Urogynecol J Pelvic Floor Dysfunct 2007;18:309-13. </P >     <p><a href="#top74">74</a> <a name="74"></a>-Fultz NH, Herzog AR. Measuring urinary    incontinence in surveys. Gerontologist 1993;33:708-13. </P >     <p><a href="#top75">75</a> <a name="75"></a>-Kirschner-Hermanns R, Scherr PA,    Branch LG, Wetle T, Resnick NM. Accuracy of survey questions for geriatric urinary    incontinence. J Urol 1998;159:1903-8. </P >     ]]></body>
<body><![CDATA[<p><a href="#top76">76</a><a name="76"></a> -Luber KM. The de&#64257;nition, prevalence,    and risk factors for stress urinary incontinence. Rev Urol 2004;6 (Suppl 3):    S3-9. </P >     <p><a href="#top77">77</a><a name="77"></a> -ICIQ. <a href="http://www.iciq.net/index.html" target="_blank">http://www.iciq.net/index.html</a>.    2006 [cited; Available from: </P >     <p><a href="#top78">78</a><a name="78"></a> -Tourangeau R, Yan T. Sensitive questions    in surveys. Psychol Bull 2007;133:859-83. </P >     <p><a href="#top79">79</a><a name="79"></a> -Rhodes T, Girman CJ, Jacobsen SJ,    et al. Does the mode of questionnaire administration affect the reporting of    urinary symptoms? Urology 1995;46:341-5. </P >     <p><a href="#top80">80</a> <a name="80"></a>-Feveile H, Olsen O, Hogh A. A randomized    trial of mailed questionnaires versus telephone interviews: response patterns    in a survey. BMC Med Res Methodol 2007;7:27. </P >     <p><a href="#top81">81</a> <a name="81"></a>-Galan I, Rodriguez-Artalejo F, Zorrilla    B. [Telephone versus face-to-face household interviews in the assessment of    health behaviors and preventive practices]. Gac Sanit 2004;18:440-50. </P >     <p><a href="#top82">82</a><a name="82"></a> -Kempf AM, Remington PL. New challenges    for telephone survey researchin the twenty-&#64257;rst century.Annu Rev Public    Health 2007;28:113-26. </P >     <P   ><a href="#top83">83</a><a name="83"></a> -Aday LA. Designing and Conducting Health    Surveys, 2nd ed.: Jossey-Bass Inc 1996:126-7. Dr.&ordf; So&#64257;a Correia  </P >     <P   ><a href="#top84">84</a><a name="84"></a> -Groves RM. Nonresponse rates and nonresponse    bias in households surveys. Public Opin Q 2007;70(5, Special Issue 2006):646&ndash;75.  </P >     <P   >&nbsp;</P >     ]]></body>
<body><![CDATA[<P>&nbsp;</P>      <P><b>Correspond&ecirc;ncia:</b></P>     <P>Servi&ccedil;o de Higiene e Epidemiologia </P>     <P>Faculdade de Medicina da Universidade do Porto </P>     <P>Alameda Prof. Hern&acirc;ni Monteiro</P>     <P> 4200-319 Porto </P>      <P>e-mail: <a href="mailto:scorreia@med.up.pt">scorreia@med.up.pt</a> </P>      ]]></body><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Incontinência urinária feminina.]]></article-title>
<source><![CDATA[Rev Port Clin Geral]]></source>
<year>2005</year>
<volume>21</volume>
<page-range>11-20</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
